Published in Women's Health Weekly, December 9th, 2004
"We hope the development of Nestorone MDTS as a transdermal contraceptive will offer women and couples a new option in meeting their family planning needs with confidence and ease. This first study will provide us with the information necessary before we begin the contraceptive efficacy trial," said Sandra Arnold, the Population Council's vice president of corporate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.